Empowered Patient Podcast-logo

Empowered Patient Podcast

Health, Home & Life

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

Location:

San Diego, CA

Description:

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

Twitter:

@karenjagoda

Language:

English


Episodes
Ask host to enable sharing for playback control

New Scaffold for Treating Severe Peripheral Artery Disease Below the Knee with Jennifer Jones-McMeans Abbott and Dr. Brian DeRubertis

6/19/2024
Jennifer Jones-McMeans, divisional vice president of global clinical affairs at Abbott’s vascular business, and Dr. Brian DeRubertis, a doctor at the New York-Presbyterian Weill Cornell Medical Center, shine a light on peripheral artery disease and critical limb-threatening ischemia where artery blockage restricts blood flow to the lower legs. Abbott has developed the Esprit, a dissolving scaffold that opens up the artery in the blocked area and elutes a drug that slows disease progression. Their LIFE-BTK trial demonstrated success in a diverse patient population and is a significant new treatment option for CLTI. Brian explains, "One of the things that I’ll say is our group is starting to explore doing additional efforts at patient education with our own patients, patients who have actually been diagnosed with this disease, and educating them a little bit more about what it means to have this disease, how they can be involved in the process of trying to prevent their disease from getting worse. And the reason we’re doing this is exactly what you said. Everyone knows what a heart attack is, but very few people understand that the same process that leads to clogged arteries in the heart or blocked arteries in the heart can lead to blocked arteries in the legs. Those blockages can ultimately lead to amputation. And so, the education of patients and keeping them informed about the disease process is one important part of this." Jennifer elaborates, "This is really a landmark moment for people with this severe form of peripheral artery disease, which we’re calling CLTI. When you think of these minimally invasive procedures to treat this disease, currently in the United States, you only have plain balloon angioplasty. And this is what the LIFE BTK trial was measured against. The Esprit was measured, which is our dissolving stent, and tested against the standard of care, plain balloon angioplasty. And it’s been decades since there’s been any innovation in this, what they sometimes call the endovascular first space. The Esprit is made out of a polymer material similar to what you would think about with dissolving stitches, and it also has a drug on it." #Abbott #CLTI #PeripheralArteryDisease #PAD #LegArteries #PlainBalloonAngioplasty #DiversityinClinicalTrials abbott.com Download the transcript here

Duration:00:22:08

Ask host to enable sharing for playback control

Developing Essential Tremor and Other CNS Therapies with Marcio Souza Praxis Precision Medicines

6/18/2024
Marcio Souza, President and CEO of Praxis Precision Medicines, discusses the challenges in treating central nervous system disorders and is focused on developing life-altering treatments for patients with essential tremor. Current treatments for epilepsy are often broad-based and not specific to the underlying cause of the disease. Praxis is using insights about genetic epilepsy to understand the underlying imbalances in the brain and develop a precision medicine approach to improve movement disorders. Marcio explains, "For example, we have four clinical programs right now, four different molecules in the clinic, and many more to come in the future, but four at this given point in time. And one of them is for a very common movement disorder called the essential tremor, which is very common, about 2% of the US population develop this condition. And there is no real understanding of where it comes from. Incredibly debilitating for all the people living with essential tremor. But when you take a step back, and you look into the network, it overlaps with a lot of our understanding of epilepsy." "Other times, we just start in epilepsy, and we end in epilepsy. And I think that’s good as well because there is a huge need for better drugs in epilepsy as well. So we’re using that as a gateway to either better drugs for epilepsy or new drugs in the case of certain types of epilepsy that don’t have any drugs or any treatment available at all. Or to branch out and really understand more mechanistically how to help other diseases. And we think it’s only the beginning. There’s a lot more to be done there." #PraxisMedicines #EssentialTremor #NeurologicalDiseases #MovementDisorder #FirstinClassMechanism #AtHomeTrial praxismedicines.com Download the transcript here

Duration:00:19:10

Ask host to enable sharing for playback control

Driving Interoperability and Ubiquitous Access to Healthcare Information with Dr. John Blair MedAllies

6/17/2024
Dr. John Blair, CEO of MedAllies, was created to address the lack of communication and coordination between healthcare providers and the importance of interoperability in healthcare. While healthcare has become more complicated over the years, with advancements in technology and automation, the lack of reimbursement for coordination of care has contributed to the problem of lack of interoperability. There are incentives and penalties associated with interoperability, including information blocking and the Trust Exchange Framework and Common Agreement (TEFCA) initiative, which aims to standardize interoperability platforms and reduce barriers to entry for healthcare organizations. John explains, "But if you look at hospitals, you've got about 70% of the hospitals in the country connected to a national network. That means there's 30% that are not. And then, if you start to break that down and look at rural areas versus urban, there's a big disconnect. These smaller rural hospitals tend to be far less connected than the larger urban hospitals. Then, if you even break it down in the urban areas, you look at certain areas, the more marginalized communities, and again, those hospitals are less likely to be connected. So that's the real issue right now as we're trying to move with interoperability, and as we're making more and more success or having more and more success, there are still those who are falling behind." "Well, interoperability should improve care and care for an individual, the experience for the individual, the efficiency of the individual getting their care amongst multiple providers, and also improve the efficiency for providers in terms of coordination between other providers. And it will cost money to do that. I mean, it costs money for those connections to run these platforms -- millions and millions of dollars to run these annually." #MedAllies #HealthcareNetworks #Hospitals #Interoperability #HealthcareCosts #TEFCA medallies.com Download the transcript here

Duration:00:21:15

Ask host to enable sharing for playback control

Universal Approach to Cell Therapy Using SNAP-CAR with Dave Mehalick Coeptis Therapeutics

6/12/2024
Dave Mehalick, Chairman, Co-Founder, President, and CEO of Coeptis Therapeutics, focuses on developing cell therapies for oncology and respiratory diseases. They aim to create a universal cell therapy that can be used for various types of cancer and move it from a later line of treatment to a frontline therapy. The company has developed a unique CAR therapy called SNAP-CAR, which utilizes off-the-shelf cells and a targeting mechanism to attack cancer cells at different points, making it difficult for the cells to mutate and evade treatment. Coeptis is conducting clinical trials using its cell generation platform, including a trial for COVID-19 patients and a trial for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients. Dave explains, "Coeptis is a cell therapy company mainly focused on oncology, although we have recently broadened into respiratory disease. And really, the prime mission of the company would be to what we would term universalized cell therapy to make it available for the masses. Right now, cell therapy has to be very highly targeted to certain people. It’s extremely expensive. With a lot of the technologies that Coeptis has brought together under one roof, we feel it will solve a lot of those issues and make it not only available to mostly all people but also move it from a third, fourth, and fifth-line therapy for different issues, all the way up to a frontline therapy." "We were able to license an amazing cutting-edge, next-generation CAR therapy developed at the University of Pittsburgh called SNAP-CAR. If you are familiar with CAR therapies such as CAR T, which have developed over the years, I believe it was initially founded at the University of Pennsylvania. Still, CAR T therapy has been rather successful in being able to attack previously thought of incurable cancers and create great results for patients." "The interesting thing about a CAR T is that each CAR T is a very highly specialized cellular structure that is designed to target a very specific point on a very specific cancer. What happens with that is when you devise it, it will be used for this exact area. And what the scientists at the University of Pittsburgh and in collaboration with Coeptis now have designed is a CAR, which is the cellular CAR, the construct that is universal. What I mean by that is it’s not initially targeting anything on a cell. We’ve created the CAR that we attach to the effector cell, whether it be a natural killer or a T cell, a macrophage, etc. However, CAR does not instantly attack anything until we use a targeting mechanism. In this case, we’re utilizing monoclonal antibodies right now that fuses with the CAR and then pulls that into attack itself. So why is that important?" #Coeptistx #Oncology #OncNews #CellTherapy #Immunotherapy #CART #CARNK #NKCells #AML #MDS #COVID coeptistx.com Download the transcript here

Duration:00:19:11

Ask host to enable sharing for playback control

Unlocking the Power of CRISPR Technology for Drug Development with Ross Bundy CRISPR QC

6/11/2024
Ross Bundy, President and CEO of CRISPR QC, shines a light on the current state of CRISPR gene editing technology and how the field has advanced rapidly since the discovery of CRISPR's potential to edit the human genome. The focus of CRISPR technology has primarily been on curing rare and genetic diseases, but there is also potential for targeting cancer tumors' resistance to chemotherapy and the development of customized therapies for various indications. The services offered by CRISPR QC include a unique sensor platform and data analytics capability to monitor and control the gene editing process. The company aims to create a database of information to improve the understanding and control of CRISPR chemistry. The CRISPR Chip is a new semiconductor technology that integrates carbon electronics to analyze complex biological processes. Ross explains, "What we find is that it can be very difficult to get that chemistry to target exactly in the right place. We don’t know yet how much the right amount is. Is it too much, too much? Is too little, too little? How do we get all these correctly into the cell? How do we deliver them to the right place? Sometimes CRISPR edits in the wrong place, it can edit multiple places across the genome, the target, and a few other places we don’t want to edit, and the cell goes and repairs it, and now we’ve changed the DNA somewhere else. So we definitely don’t want that. If we’re going to edit DNA, we want to edit just the part we want, and we don’t want to change anything else. So, the challenge today is that we don’t know exactly how this chemistry works. It is still a very new field." "We’re saying, can we open up that black box and say, here’s all the gears and all the levers, all the buttons, and the pharma companies can now then precisely control this chemistry and deliver the result that they want. So that’s what we’re able to start doing for the field. This is the maturation of a new science coming out, proving it’s capable, and now moving to an industrial process. We’re helping transition that industrial process." #CRISPRQC #CRISPR #CRISPRCas9 #GeneEditing #CellularGeneTherapy CRISPRQC.com Download the transcript here

Duration:00:19:27

Ask host to enable sharing for playback control

Therapeutic Cancer Vaccines with Nicolas Poirier OSE Immunotherapeutics

6/10/2024
Nicolas Poirier, CEO of OSE Immunotherapeutics, uses immunology and molecular engineering to develop innovative immunotherapies for oncology, inflammation, autoimmune diseases, and organ transplant. The same immune cells, lymphocytes and macrophages, are involved in both immuno-oncology and immuno-inflammation, and OSE aims to re-educate these cells to recognize and eliminate cancer cells or restore immune tolerance in autoimmune diseases. He also discusses the potential of cancer vaccines in re-educating the immune system to target cancer cells, and the importance of combination therapies in improving treatment outcomes. Nicolas explains, "There are two big families in the immune system. We have the adaptive immunity generated by lymphocytes. We have several types of lymphocytes: T-lymphocytes, B-lymphocytes, and so on. This is a very specific immune response that humans and other species have developed to recognize, very specifically some antigens from viruses, for tumors, and so on. We can control these cells." "On the other side, there is innate immunity composed of macrophages, NK cells, or others, and this is a non-specific immune response that recognizes either danger signals or pathogen signals. These are mostly the elements that are implicated in many chronic inflammatory diseases. Still, there are also some elements that we can manipulate or re-educate in oncology to help the immune system globally work better. Because these lymphocytes and these macrophages, this adaptive immunity or innate immunity, work together, and all together, we can re-educate and orchestrate this immune response in a good direction." "There's a big promise and big hope now in the field of therapeutic cancer vaccines. It's important to understand that it's therapeutic. It means we're not yet able to prevent cancer development, this might be in the future, but we use cancer vaccines to re-educate the immune system of patients that have developed a tumor. It's a therapeutic drug, and we're developing one of the most advanced therapeutic cancer vaccines in the world with the upcoming new registration phase three in lung cancer patients in second line." #OSEImmunotherapeutics #Cancer #LungCancer #CancerVaccine #ImmuneSystem #Macrophages #Inflammation #InflammatoryDisease ose-immuno.com Download the transcript here

Duration:00:20:17

Ask host to enable sharing for playback control

Innovative Blood Collection Device Boosts Participation in Decentralized Clinical Trials with Ben Casavant Tasso

6/5/2024
Ben Casavant, Co-Founder and CEO of Tasso, focuses on making diagnostics more accessible to patients that allow collection of blood samples at home. Their customers include pharmaceutical companies conducting research and healthcare providers. Using Tasso's technology in decentralized clinical trials allows for easier recruitment, increased patient participation, and more data collection. The simplicity and ease of use of Tasso's blood collection device have resulted in positive patient responses and improved retention rates in clinical trials. They offer liquid and dried blood collection options to accommodate different lab processes and sample types. Ben explains, "When we think about the customer bases we're serving, we're working with many different pharmaceutical companies conducting critical and life-changing research. We just announced a partnership with the Parkinson's Foundation so they can help find ways to gather information and data about patients living with Parkinson's disease. But they need that access and data from patients. By working with Tasso, we enable them to have that reach and accessibility." "When we're working with various pharmaceutical companies. They're seeing this real need to get subjects into their trials, to ease recruitment, to help make sure they're hitting their recruitment targets. To help make sure that as a patient goes through a clinical trial, they're able to meet all the data points that are needed so that they can have a completed data set for their own submission. And broadly, in that industry, we're seeing this huge shift. It's really exciting that pharma companies, sponsors, and CROs are looking for more tools to provide patients with better access and lower the barrier, lowering the bar for people to participate in these trials." #Tassoinc #DecentalizedClinicalTrials #DCT #ClinicalTrials #HealthTechnology #HealthTech tassoinc.com Download the transcript here

Duration:00:19:18

Ask host to enable sharing for playback control

AI-Powered Device Provides Real-Time Screening for Early Detection of Heart Failure Symptoms with Chris Darland Peerbridge Health

6/4/2024
Chris Darland, President and CEO of Peerbridge Health, discusses technology breakthroughs that enable early, low-cost detection of heart issues with a cardiac monitor that uses AI to analyze heart rhythms over time to detect patterns that may indicate heart failure. The device is based on ECG technology that drives the Holter monitor and delivers a full 12-lead ECG with a volumetric 3D view of the heart. The goal is to reach more patients who may not proactively seek medical attention and provide early intervention and treatment. Chris explains, " I think the problem with the current state is largely that it's too late. And I say that to mean that 80% of all heart failure cases today are getting caught after an emergency room visit. So, it's not necessarily that we don't have the tools to find heart failure and the cardiologists and expertise to identify it, but we're not getting it in time. So if you are one of those patients who, let's say, are caught earlier or maybe unfortunately when you come through the ER, a lot of the tools are existing in the hospital. So you'll get an ultrasound, an echo, to get a view of your heart. We'll do an ECG in the hospital and potentially a cardiac MRI. There's a suite of tools available in the acute care setting that can get to this conclusion relatively quickly if you have all the tools right in front of you." "The nice part about it is it's relatively accepted from a workflow perspective, a tool that's used quite commonly and has become exceedingly convenient over the last five to 10 years. There is a lot of innovation in a handful of companies to make it easy to wear, light, waterproof, etc. And when we think through the innovation we're working through right now, it's essentially using that tool and the output of this ambulatory cardiac monitor that we have in Peerbridge. Then doing some interesting AI advanced diagnostics on top of it to pick up patterns that were maybe lost historically or potentially missed based on signal fidelity of devices that were in the market. Then using those patterns to try to get a head start on heart failure diagnosis as well as a handful of other things we can show they do." #PeerbridgeHealth #Cardiology #Cardiologists #ECG #HeartHealth #HeartFailure #EarlyDetection #RemotePatientMonitoring PeerbridgeHealth.com Download the transcript here

Duration:00:19:13

Ask host to enable sharing for playback control

Partnering with Retail Pharmacies to Make Blood Testing More Convenient and Accessible Dr. David Stein Babson Diagnostics

6/3/2024
Dr. David Stein, CEO and Director of Babson Diagnostics, a healthcare technology company that focuses on putting the patient at the center of the blood testing experience, recognizing the importance of blood testing in informing clinical decisions and monitoring health. They aim to redefine blood testing by eliminating the anxiety and inconvenience associated with traditional blood testing methods by offering a more accessible and convenient approach. Blood samples are collected with an innovative device from the patient's fingertip at retail pharmacy locations, and patients use a digital app and QR code system to order and track tests and receive test results. David explains, "Babson Diagnostics is a science-first healthcare technology company that has reimagined the end-to-end blood testing experience. In that experience, the patient and customer are the strong focus. We've all experienced times when we've had a blood test ordered for us, and we’ve felt anxious. We've tried, as much as we can, to eliminate that, both by the location where we provide the service, which is the retail pharmacy, and also through our approach, where we easily take samples from your finger, wrap it in a digital layer to make it all understandable. In the end, provide a preferred experience that is much more convenient and accessible than what you experience today." "Probably the more important thing is how can we make it so that you don't have to get venipuncture, so that you don't have to get a needle in your arm, because for a significant part of our population, having a sharp object inserted in your body, is not something most of us like. So, in reality, between vasovagal issues and difficult veins, people are looking for a true alternative." "People are also looking for accessibility and convenience. What we have innovated is in both aspects. One is to allow you to do broad, clinical-grade testing with a sample that's easily collected from your fingertip while also being able to get that collection done in locations near your home, such as your local supermarket or your local pharmacy. We've tried to innovate in two aspects, which is what everybody wants -- accessibility and convenience. We see that in every part of our economy and have changed the way that blood is collected so that you don’t have the anxiety of a needle going in your arm." #BabsonDiagnostics #BloodTesting #Pharmacies #BetterWay #MedicalDevice #MedTech BabsonDX.com Download the transcript here

Duration:00:17:28

Ask host to enable sharing for playback control

Impact of AI on Reducing Waste and Friction in Healthcare Administration with Joan Butters Xsolis

5/30/2024
Joan Butters, CEO and Co-Founder of Xsolis works with health systems and health plans to automate medical necessity decisions and improve efficiency. Using data and AI, Xsolis helps clinicians make more informed decisions and reduces manual administrative work, resulting in time and cost savings and improved patient care. Addressing the challenges and pushback faced when introducing AI into healthcare, Joan emphasizes the importance of understanding the limitations and complexities of generative AI and the need for subject matter expertise in developing prompts to properly address friction points between providers and payers in the healthcare environment. Joan explains, "More important to this audience are the administrative aspects and the impact of that back and forth on the cost of healthcare. We were very fortunate that we found a niche in what we were trying to solve for. Again, that was the medical necessity decision whether a patient required hospital-based care. And then, with that laser focus, we did a lot of research from both sides and found that there was a way to automate through the use of data and AI to solve some of those problems." "There are definitely two areas that we have a direct impact on. As I said, one is the cost of healthcare—so big efficiency. If you think about what clinicians do when they're making a determination of hospital-based care, prior to Xsolis, those clinicians would be reading through multiple data points and not data points that were connected, which became a very manual process. With automation and artificial intelligence, our system allows that very costly staff to be much more efficient in making those determinations. Coupled with that, instead of clinicians doing administrative tasks, the automation we provide through AI and our technology frees the clinician to be back at the bedside with the patient." #Xsolis #Healthcare #HealthcareAdministration #Workflow #RemovingWorkflowFriction #AI #MedicalNecessityDecisions #Clinicians xsolis.com Download the transcript here

Duration:00:16:07

Ask host to enable sharing for playback control

Cancer Molecular Profiling Using Next-Generation Sequencing to Treat Rare Diseases with Sanjeev Redekar Apollomics

5/29/2024
Sanjeev Redkar, Co-Founder, Executive Director, and President of Apollomics, focuses on difficult-to-treat cancers, such as lung cancer, brain cancer, and leukemias, not served by immune checkpoint inhibitors. Their approach targets the thematic pathway in cancer cells responsible for their growth and proliferation. In their drug development, AI and data analysis drive precision-targeted therapies based on tumor molecular profiling. They are developing the drugs Vebreltinib and Uproleselan, which can be used as standalone treatments or in combination with other therapies to treat rare cancers. Sanjeev explains, "There's a pathway that is very important for the growth of cancer cells. This is proliferation, motility, migration, and invasion of cancer cells, and that's the thematic pathway. This is an important receptor, which is upstream in cell signaling of these cancer cells. This is when these pathways work well, these cells grow as normal homeostasis, normal growth of cells. When this pathway is disrupted in cancer cells, they tend to grow far more than what normal cells would. That's the pathway that we are going after. These are mutations in this pathway, in the genome amplification, gene amplification, and fusions, which lead for these particular cancers to grow well. If you are able to inhibit that pathway, then you are able to impart benefit to the patient. And that's what one of our main drugs, Vebreltinib, is going after." "As a whole, in lung cancer, even though the checkpoint inhibitors have moved the needle in terms of five-year survival rates, the needle has been moved from about 25% to about 30%, 32%, which is still much lower than say breast cancer, prostate cancer, where the five-year survival rates are close to 80%, 90%. So, how we can win the battle against lung cancer and brain cancer is really using precision-targeted therapies. These slivers of cancers that have a particular mutation, that have a particular dysregulation, and having treatments for that allow these patients a targeted approach for a longer benefit as opposed to one treatment for the entire lung cancer population. That is why we go after the so-called slivers, which put them into the rare cancers bucket." #Apollomics #RareDiseases #Cancer #LungCancer #Leukemias #BrainCancer #RareCancers #NextGenSequencing #MolecularProfiling #CancerMolecularProfiling #TumorMolecularProfiling #AI Apollomics.com Download the transcript here

Duration:00:17:45

Ask host to enable sharing for playback control

Redefining Healthcare for Women Over 65 with Kristen Helton Herself Health

5/28/2024
Kristen Helton, CEO and Co-Founder of Herself Health, provides comprehensive primary care designed specifically for women over 65, considering the unique health challenges these women face. The emphasis is on the importance of addressing women's health beyond reproductive health and the need for tailored treatment and screening for conditions that affect women differently than men. Kristen notes the underrepresentation of women, especially older women, in clinical trials and the need for further investigation. They aim to reduce bias and improve the quality of care for older women by adopting a person-centric approach, listening to patients' concerns, and building trust. Kristen explains, "Almost half of the burdens of disease that women experience stem from conditions that affect women differently than men. So, a lot of these diseases, cardiovascular, chronic illness, gastroenterology, and depression, affect men differently than they affect women. We're very focused on how we treat women and screen them for different diseases. We take a really comprehensive health history. Women have a lot of data that we need to understand as we're putting together the picture of their overall health." "I mean, 65 is young old, in fact. It's just the beginning, and there are a lot of differences between 65 and 75 and 85 and 95. We're talking about decades. So I'm also remiss in grouping 65 and up even into a single category. But you hit on something super important there, and that is women are not satisfied with the answer that's just what happens as you get older. It comes back to, in essence, the quality of life. I think this is where we're seeing some real success in our approach, which is yes, we want to do all of the important preventative, physical, behavioral health care. But we also want to understand the patient's goals and what they're trying to get to and maintain." #HerselfHealth #WomensHealth #Healthcare #ValueBasedCare #PrimaryCare herself-health.com Download the transcript here

Duration:00:19:07

Ask host to enable sharing for playback control

Redefining Healthcare for Women Over 65 with Kristen Helton Herself Health

5/28/2024
Kristen Helton, CEO and Co-Founder of Herself Health, provides comprehensive primary care designed specifically for women over 65, considering the unique health challenges these women face. The emphasis is on the importance of addressing women's health beyond reproductive health and the need for tailored treatment and screening for conditions that affect women differently than men. Kristen notes the underrepresentation of women, especially older women, in clinical trials and the need for further investigation. They aim to reduce bias and improve the quality of care for older women by adopting a person-centric approach, listening to patients' concerns, and building trust. Kristen explains, "Almost half of the burdens of disease that women experience stem from conditions that affect women differently than men. So, a lot of these diseases, cardiovascular, chronic illness, gastroenterology, and depression, affect men differently than they affect women. We're very focused on how we treat women and screen them for different diseases. We take a really comprehensive health history. Women have a lot of data that we need to understand as we're putting together the picture of their overall health." "I mean, 65 is young old, in fact. It's just the beginning, and there are a lot of differences between 65 and 75 and 85 and 95. We're talking about decades. So I'm also remiss in grouping 65 and up even into a single category. But you hit on something super important there, and that is women are not satisfied with the answer that's just what happens as you get older. It comes back to, in essence, the quality of life. I think this is where we're seeing some real success in our approach, which is yes, we want to do all of the important preventative, physical, behavioral health care. But we also want to understand the patient's goals and what they're trying to get to and maintain." #HerselfHealth #WomensHealth #Healthcare #ValueBasedCare #PrimaryCare herself-health.com Download the transcript here

Duration:00:19:07

Ask host to enable sharing for playback control

Modifying Macrophages to Overcome Evasion by Cancer Cells and Educate Immune System with Robert Towarnicki SIRPant Immunotherapeutics

5/23/2024
Robert Towarnicki, CEO and Co-founder of SIRPant Immunotherapeutics, discusses cancer-specific immunotherapy for aggressive tumors, the role macrophages play in the immune response to cancer, and how cancer cells can shut down this response. SIRPant Immunotherapeutics aims to modify macrophages by reducing SIRPα expression, triggering them to eat cancer cells and educate other immune cells. Early evidence demonstrates potential effectiveness for various cancers, including non-Hodgkin's lymphoma and solid tumors. Robert emphasizes this therapy's scalability and cost advantages compared to other cell therapies like CAR-T. He also highlights the potential for treating rare diseases and the ability of SIRPant-M to target a wide range of cancers without the need for pre-identified targets. Robert explains, "Macrophages are a normal immune cell type in your body. They normally function to recognize foreign invaders and process them in the sense of phagocytizing or eating the foreign protein and invader, if it's a virus, a bacteria, or a cancer. Unfortunately, cancers are very good at shutting down this immune response. So, we need to modify the macrophage and re-empower it to elicit the other immune cells in the body to do their job and eliminate cancer." "I think one of the mistakes we've seen with others working with the macrophage in this situation was the lack of appreciation for the role of SIRPα. Our inventor, Dr. Yuan Liu at Georgia State University, identified this early on through a knockout mouse, a mouse where SIRPα was genetically removed from it. With that mouse, she could discover and learn how macrophages function and react. It directed us to the whole concept of removing SIRPα from the macrophage. Now, removal alone is not enough. You also have to activate a macrophage. So, a macrophage exists in multiple states. There's an active state, and then there's an inactive state." #SIRPant #Immunotherapy #Macrophages #Oncology #Cancer sirpantimmunotx.com Download the transcript here

Duration:00:24:52

Ask host to enable sharing for playback control

Power of AI and Data Analytics to Improve Patient Safety Risk Management with Jeff Surges RLDatix

5/22/2024
Jeff Surges, CEO of RLDatix, offers global cloud-based solutions for risk management, compliance management, and regulatory management in healthcare. To address patient safety, Jeff emphasizes the need for a collaborative workforce, data analytics, and AI. RLDatix uses technology to automate information gathering, facilitate incident reporting, and analyze data to determine proactive actions to prevent incidents and improve safety. Jeff explains, "The simplest analogy when I get asked this is: how does this relate to other industries? We all fly in airplanes, and we've seen in the airline industry most recently with doors coming off, the emergency exit doors, close calls, or what we'll call incidents where you need to look at the root cause. The key difference is if a plane goes down, as tragic as that is, the pilots and the crew go down. But in healthcare, if there's an incident or a procedure or an event that has occurred, it's likely only affecting the patient and the patient's family. That's not meant to say that people don't care, everybody cares, but it doesn't affect the entire circumference. What we try to do is make it automated, make it easy to use, engage with what we call a culture of safety, which starts at the very highest level, and then using data analytics, now, generative AI." "For 20 years, an article written in our industry called To Err Is Human kicked off the energy around improving patient safety. I think the first phase of that for over ten years, 15 years, was just documenting the event after it happened. Let's document. Let's run around and automate, document, and report on it." "Today, that's no longer the case. All of our customers and our industry want to prevent this. We use terms like highly reliable- I want to be an HRO, a highly reliable organization. We're competing on safety. Everybody wants to go to the safest place for care. We're trying to use data and analytics to both prevent and gain the insights to make sure that we can continue that not just one time. The data is telling us there are some decisions we can make in our policies and our procedures, in our staffing levels, and in our credentialing of staff to make sure that we can continue. So, going from reactive to proactive risk mitigation." #RLDatix #ConnectedHealthcareOperations #PatientSafety #HealthTech #AI rldatix.com Download the transcript here

Duration:00:17:39

Ask host to enable sharing for playback control

Tailoring Diabetes Management Using Hybrid Closed-Loop Algorithm to Meet Individual Needs with Lou Lintereur Medtronic Diabetes

5/21/2024
Lou Lintereur, Chief Engineer for automated delivery systems at Medtronic Diabetes, brought his knowledge from working as an aerospace engineer at NASA to developing technology for those living with diabetes. He introduces the MiniMed 780G, a closed-loop system that combines an insulin pump and continuous glucose monitor (CGM) with a control algorithm that tailors itself to each patient's unique physiology and Meal Detection technology, which helps manage their blood sugar levels. Patient feedback is essential to the continuing innovation of these hybrid closed-loop tools to manage diabetes. Lou explains, "There are two main challenges we're always trying to deal with, and they kind of compete with each other. One is just the fundamental technology, trying to get the best therapy for the patients and the best outcomes for a long, healthy life where they're feeling good. With respect to diabetes, it's about keeping your blood sugar under as tight a control as possible within a normal glucose range. So that poses the technical challenges of how to design a control system to do that with all the uncertainties of human physiology and so forth." "But on the other side, the systems we make at Medtronic Diabetes are almost consumer products. In order to get the therapy that they need, the patient often has to contribute to the therapy. They need to indicate when they're eating, for example, and then help the system calculate how much they're eating so that they can dose the insulin properly to manage their meals better. It requires some cooperation with the patients. So, on that side of the challenge is, how do you make the system easy enough to use so that the patient can get the best outcomes possible and do as little work as possible? Because the last thing the patient wants to do is be bothered all the time having to manage their therapy." #MedtronicDiabetes #Diabetes #ContinuousGlucoseMonitor #CGM #InsulinPump medtronicdiabetes.com Download the transcript here

Duration:00:20:01

Ask host to enable sharing for playback control

Transparency in Coverage Rule Provides Precision of Price and Negotiated Rates for Healthcare with Mark Galvin TALON

5/20/2024
Mark Galvin, Co-Founder, President, and CEO of TALON, discusses the Transparency in Coverage rule in healthcare, which was added to the Affordable Care Act and requires commercial health plan sponsors to provide transparency in the costs of tests, procedures, and other medical services. The rule aims to provide patients with information on pricing and out-of-pocket costs before committing to services. The lack of awareness and understanding of the rule is in part due to the vested interests of certain stakeholders, such as insurance carriers, who are financially conflicted in driving down the cost of medical claims. Mark explains, "I'm known as a disruptive innovator, as a serial startup guy. The Transparency in Coverage rule is a rule that was added to the Affordable Care Act, or Obamacare, requiring that commercial health plan sponsors predominantly the employers that pay for the lion's share of commercial health plans are required now under that law with the new rule to provide to million members an ability to go from total opaqueness in price to total transparency in the costs of the tests and procedures and other things that they're faced with in their medical journeys." "The mistake many of us made as consumers is that we believed our insurance carrier was a good surrogate to represent us as consumers in the marketplace. And what we never, many of us still don't realize, but many of us kind of woke up to is there's this thing called the 80/20 rule or medical loss ratio, which puts insurance carriers in a conflicted position. Their businesses are damaged financially by driving down the cost of medical claims because their revenues and premiums are tied to the amount of medical claims." "So this is something people didn't know. And so while we put our trust in people to represent us as consumers, not realizing that it's not in their best interest to do the right things for us as consumers in terms of their normal business metrics, that it causes a huge conflict, financial conflict and perverted financial incentives in the market." #TALONHealthtech #TransparencyinCoverage #MedicalCosts #PatientCare #AffordableCareAct #ReduceHealthcareCosts #Hospitals #MedicalBills #Healthcare #HealthTech #HealthcareReform talonhealthtech.com Download the transcript here

Duration:00:20:43

Ask host to enable sharing for playback control

Deploying Technology in Decentralized Clinical Trials Improves Recruitment and Retention with Alice Lin Tigermed Consulting

5/16/2024
Alice Lin, DCT Solutions Director in the DCT Business Department of Tigermed Consulting, a global CRO, contract research organization, that provides biopharmaceutical and medical device companies with a range of services including digital technology to conduct decentralized clinical trials. Their approach focuses on patient-centricity, efficiency, and adaptability. By utilizing digital tools such as virtual visits, wearable devices, and mobile apps, Tigermed aims to make clinical trials more accessible and convenient for patients, improving recruitment and retention rates. They also emphasize the importance of DCT in including a diverse patient population in trials, particularly for rare diseases. Alice explains, "While our headquarters is in China, we have grown into a global team of over 10,000 employees operating across over 180 locations worldwide. We recently celebrated our 20 anniversary, making two decades of dedicated collaborations with over 2,800 customers on their product journeys. DCT stands for decentralized clinical trials, which involves applying digital technologies to conduct clinical trials. Traditionally, most clinical trial activities are conducted at clinical sites. Still, with DCT, we can conduct some or even all of the trial procedures outside of these sites using digital technology." "Currently, the hybrid DCT model is a common thing in clinical trials. It means some of the trial procedures could be conducted outside of clinical sites, but still keep some clinical trial activities at clinical sites. In our Tigermed DCT department, we are responsible for identifying the appropriate digital technologies for using in clinical trials, whether through self-development or collaboration with the various digital technology companies. We also manage the DCT daily operations in each clinical trial from the study beginning to the study completion." "However, we get that every investigational product and the therapeutic areas bring its own set of challenges and patient needs. So, we make it a priority to figure out what digital tools work best for each study. Our CEO, Dr. Cao, and our head of the DCT business department always say our goal is not just to do decentralized clinical trials for the sake of it. It's about giving patients and caregivers options that fit their needs. This approach means patients and caregivers get solutions that work for them, showing that we are all about being flexible to what they need. Our decentralized clinical trials are all about making things easier for patients, lightening the load for our caregivers, and making the whole trial experience better for all stakeholders involved." #TigermedGRP #CRO #ContractResearchOrganization #DCT #DecentralizedClinicalTrials #MedTech #RemoteMonitoring TigermedGRP.com Download the transcript here

Duration:00:18:50

Ask host to enable sharing for playback control

Developing Drug Targeting B Cells in Autoimmune Disease of the Kidney IgA Nephropathy with Dr. Marshall Fordyce Vera Therapeutics

5/15/2024
Dr. Marshall Fordyce, CEO and Founder of Vera Therapeutics, discusses the company's patient-centric approach to developing new medicines for autoimmune diseases. Vera is currently in Phase 3 with a molecule called Atacicept, which targets B cells in autoimmune diseases. They focus on IgA nephropathy, a rare kidney disease, and the third most common cause of kidney failure. A key concern is that declining kidney function is often misdiagnosed and not screened for because the early warning signs are so subtle. Marshall explains, "Let me give you an example of our lead indication. So, our molecule in development is called atacicept. It targets the immune system in the specific area of B cells, and B cells are the factories of our antibodies, which we need to fight infection over our lifetime. But in patients with autoimmune disease, these B cells are overstimulated, they're overactive, and there are only a few medicines that target B cells with an appropriate balance of safety and efficacy. We had an insight that the science told us that by inhibiting two key factors in the body, BAFF and APRIL, we could normalize that overactivity of B cells and have better outcomes." "Now traditional drug development may be long and expensive. We were very strategic in picking IgA nephropathy. This is an area that has had very little drug development over the last decade. A few small companies started to become interested in this area, and thankfully, because of patient advocacy, the FDA allowed a surrogate endpoint in Phase 3 trials, which made it more efficient to bring this molecule forward. So, there are now two drugs on the market for the first time in the last three or four years, for two new drugs in IgA nephropathy. They don't target B cells, which is really what's driving this disease. They work downstream, or they're nonspecific." "What Vera did differently is that we thought that we could actually demonstrate that kidney function, which in these young patients is declining at an alarming rate, if we could demonstrate that kidney function doesn't decline, that would be meaningful. It would be a significant leap. We don't see that happen in "traditional" drug development often, in my view. So, I think what's different here is that we're picking an area where we think we can intervene and, in early-stage development, show a meaningful improvement in outcomes for patients." #VeraTherapeutics #KidneyDisease #RareDisease #BCells #Immunotherapy #AutoimmuneDiseases #IgANephropathy veratx.com Download the transcript here

Duration:00:20:09

Ask host to enable sharing for playback control

Developing Drugs to Treat Rare Liver Diseases NASH PBC ACLF with Pascal Prigent GENFIT

5/14/2024
Pascal Prigent, the CEO of GENFIT, a French biotech that has been working on liver diseases for about 20 years and has developed a compound called elafibranor for conditions such as primary biliary cholangitis (PBC). The company is also developing assets in acute-on-chronic liver failure (ACLF). He highlights the high unmet medical need in ACLF, which currently has no approved treatment options and a high mortality rate. Prigent also discusses Genfit's partnership with Ipsen for the development and commercialization of elafibranor in PBC. Pascal explains, "In reality, we don't have any approved option in ACLF, which is actually quite dramatic because you have a high mortality rate. To give you a little bit of context, people are suffering from chronic liver disease, regardless of the etiology. It can be too much alcohol consumption, it could be NASH, it could be viral hepatitis. Any kind of chronic liver disease will give us all the same journey, if you will." "First, you have an injury to the liver. Then you have a progressive liver scar. You have the setup of fibrosis, that fibrosis becomes worse and worse. It becomes bridging fibrosis, but at some point, it will become cirrhosis. And that cirrhosis is first compensated, and then one day it can decompensate, and on that already failing organ, you have a precipitating factor." "That precipitating factor could be an infection, binge-drinking, or drug-induced trauma. That stress on an already sick organ will get the liver to decompensate, and that decompensation of the liver will trigger additional organ decomposition, and that's what ACLF is. It's a syndrome at the very end of chronic liver diseases." #GENFIT #LiverDisease #NASH #PBC #ACLF #LiverFailure #Hepatitis #ChronicLiverDisease #RareDisease GENFIT.com Download the transcript here

Duration:00:18:30